Analytical and clinical validation of a progranulin ELISA in the FTD disease spectrum
Francisco J. Meda(University of Gothenburg), Henrik Zetterberg(University of Wisconsin–Madison), Hlin Kvartsberg(University of Gothenburg), Ulf Andréasson(Sahlgrenska University Hospital), Valentina Cantoni(University of Brescia), Barbara Borroni(Centro San Giovanni di Dio Fatebenefratelli), Joel Simrén(University of Gothenburg), Silvana Archetti(University of Brescia), Kaj Blennow(Sahlgrenska University Hospital)
Cited by 0
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
New insights into the genetic etiology of Alzheimer’s disease and related dementias
|Nature Genetics|2022|2.5k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k